

mesalazine 1200mg gastro-resistant, prolonged release tablet (Mezavant XL[®]) **No. (445/08)**

Shire Pharmaceuticals Limited

Product Update

11 February 2008

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

mesalazine 1200mg gastro-resistant prolonged release tablet (Mezavant XL[®]) is accepted for use within NHS Scotland for the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis, and for maintenance of remission.

It may be used in cases where mesalazine is an appropriate choice of treatment and offers the possible advantage of once-daily administration.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 7 January 2008.

**Chairman,
Scottish Medicines Consortium**